Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Athira Pharma, Inc. (NASDAQ: ATHA) SEC filings page brings together the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Athira, which has announced a name change to LeonaBio, Inc. with a future ticker "LONA," uses filings such as Forms 8-K and 8-K/A to report material events related to its operations, capital structure and key licensing agreements.
Recent filings describe a 10-for-1 reverse stock split of common stock, implemented through a certificate of amendment in Delaware, and subsequent confirmation from The Nasdaq Stock Market that Athira regained compliance with the minimum bid price requirement. Other 8-K filings detail a private placement financing involving common stock, pre-funded warrants and accompanying common warrants, with gross proceeds expected to be approximately $90 million, and outline associated registration rights for investors.
Filings also cover Athira’s exclusive licensing arrangements for lasofoxifene with Sermonix Pharmaceuticals and Ligand Pharmaceuticals, including the assumption of responsibility for the global Phase 3 ELAINE-3 trial outside specified retained territories. These documents provide insight into how the company structures rights to develop, manufacture and commercialize oral forms of lasofoxifene and how it coordinates with partners.
On this page, users can review Athira’s current reports to understand how financing terms, warrant structures, reverse stock split mechanics and licensing obligations interact with its clinical programs in metastatic breast cancer and ALS. Stock Titan’s platform adds AI-powered summaries to help explain the key points of lengthy filings, highlight important dates and thresholds, and make it easier to interpret how each filing may relate to Athira/LeonaBio’s broader strategic and clinical plans.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. The award vests in equal monthly installments over 36 months, contingent on her continued service as a Service Provider under the company’s 2026 Equity Incentive Plan. Following this grant, she holds 56,000 stock options directly.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. They vest monthly over 36 months, contingent on his continued service to the company.
Following this grant, Silverman holds 56,000 stock options directly, reflecting a compensation award rather than an open-market share purchase or sale.
LeonaBio, Inc. director Callori Fred received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. All 56,000 options are held directly after this award.
The options are scheduled to vest in equal installments monthly over 36 months from the grant date, as long as the director continues to serve as a service provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Peter B. Silverman filed an initial Form 3 as a reporting person for the company. The filing lists him as a director but shows no reported purchases, sales, or other transactions in LeonaBio securities, and no derivative holdings in this snapshot.
LeonaBio, Inc. filed an initial Form 3 identifying Natalie C. Holles as a director and reporting person for the company’s securities. The filing does not report any transactions or holdings, serving mainly to establish her status under insider reporting rules.
LeonaBio, Inc. director Callori Fred filed an initial Form 3 to report insider status with the company. The filing lists no stock purchases, sales, option exercises, gifts, or other transactions, indicating this is a baseline ownership disclosure rather than a record of trading activity.
Perceptive Advisors and affiliates report owning 1,882,370 shares of LeonaBio common stock, representing 19.99% of the class. The stake includes 1,552,614 shares, or 16.5%, held by Perceptive Life Sciences Master Fund, Ltd. and 352,804 shares, or 3.7%, held by Perceptive Xontogeny Venture Fund II.
The ownership percentages are based on 9,393,514 shares of common stock outstanding and give effect to warrants allowing purchase of 23,048 additional shares subject to limits. A Beneficial Ownership Limitation prevents exercises that would take the group above 19.99%. On May 5, 2026, Fred Callori, a Partner and Managing Director at Perceptive Advisors, was appointed to LeonaBio’s board of directors. The filers report no transactions in the company’s stock during the prior sixty days.
LeonaBio, Inc., a clinical-stage biopharma company, reported a net loss of $32.9M for the quarter ended March 31, 2026, compared with $9.1M a year earlier. The larger loss was driven by higher research and development spending and a $16.3M non-cash loss from remeasuring the Sermonix pre-funded warrant before it was reclassified to equity.
Research and development expenses rose to $11.3M, mainly reflecting investment in lasofoxifene and ATH-1105, while general and administrative costs increased to $6.9M. Cash, cash equivalents and investments totaled $67.7M, and management believes this will fund operations for at least 12 months based on the current plan.
LeonaBio, Inc. reported first quarter 2026 results and highlighted progress in its oncology and neurodegeneration pipeline. The company is running the Phase 3 ELAINE‑3 trial of lasofoxifene in ER‑positive, HER2‑negative, ESR1‑mutated metastatic breast cancer, plans to increase enrollment to up to 600 patients, expects to complete enrollment in 4Q 2026 and to report topline data in the second half of 2027.
ATH‑1105, an oral, brain‑penetrant candidate for ALS, showed favorable safety, pharmacokinetics and CNS penetration in a Phase 1 trial, and LeonaBio aims to start a Phase 2 proof‑of‑concept study in ALS patients in the second half of 2026. Cash, cash equivalents and investments were $67.7 million as of March 31, 2026, compared with $88.3 million as of December 31, 2025, reflecting higher operating spend.
Research and development expenses rose to $11.3 million for the quarter from $4.3 million a year earlier, mainly from the ELAINE‑3 trial, while general and administrative expenses increased to $6.9 million from $5.2 million. Net loss widened to $32.9 million, or $1.73 per share, from $9.1 million, or $2.34 per share, driven in part by a non‑cash $16.3 million change in fair value of a Sermonix pre‑funded warrant.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.